Adipotide
Also called Prohibitin-TP01; FTPP
An experimental compound designed to destroy the blood supply of white fat tissue. It caused weight loss in monkeys, but kidney damage appeared in the same studies, and the only human trial ended with four participants and no results.
Overview
What it is
A two-part molecule: one segment targets prohibitin on blood vessels feeding white fat, and the other triggers cell death.
How it works
By damaging the vessels that supply fat tissue, it aims to shrink fat stores. This is different from appetite-based GLP-1 medicines. "Targeted" is a design goal, not a guarantee that other organs are spared.
What the research shows
A 2011 study in obese monkeys reported reduced weight and fat and better insulin resistance; average weight loss was about 11% over four weeks, with regain after stopping. A phase 1 trial in men with prostate cancer and obesity (NCT01262664) enrolled four people and was terminated at the investigator's request with no posted results.
Studied for
- Weight and fat lossmonkeys
- Insulin resistancemonkeys
Safety and regulatory status
Safety and side effects
Dose-related kidney injury and changes in blood and urine tests appeared in the monkey studies. Many changes improved after stopping, but that does not mean harm is predictable or reversible in people.
Regulatory status
Not approved by the FDA for any use.
Mixing and dosing reference
Reference information only. Read before using this section.
Adipotide (5 mg Vial) Dosage Protocol
- Vial
- 5 mg Adipotide
- Add diluent
- 1.5 mL
- Concentration
- 3.33 mg/mL
- 1 unit (U-100)
- 33.33 mcg in 0.01 mL
- Route
- Subcutaneous
- How often
- Once per day (subcutaneous).
- Typical range
- 250–1000 mcg daily with gradual titration every 2 weeks.
- Cycle length
- 4–8 weeks (based on preclinical effective treatment duration; extend with extreme caution).
Standard / Gradual Approach
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 250 mcg | 7.5 units (0.08 mL) |
| Weeks 3–4 | 500 mcg | 15 units (0.15 mL) |
| Weeks 5–6 | 750 mcg | 22.5 units (0.23 mL) |
| Weeks 7–8 | 1000 mcg (1.0 mg) | 30 units (0.30 mL) |
How to mix
- Draw 1.5 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Dosing details
- Start: 250 mcg daily for Weeks 1–2; increase by 250 mcg every 2 weeks as tolerated.
- Target: Up to 1000 mcg (1.0 mg) daily by Weeks 7–8 (if well‑tolerated).
- Frequency: Once per day (subcutaneous).
- Cycle Length: 4–8 weeks (based on preclinical effective treatment duration; extend with extreme caution).
- Timing: Any consistent time; rotate injection sites systematically.
Storage
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Administration technique
- Clean the vial stopper and skin with alcohol; allow to dry fully.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue (45° if limited subcutaneous fat, 90° if ample tissue).
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy and local irritation.
- Wait a moment before withdrawing the needle; apply gentle pressure but do not rub the injection site.
Important notes
- Use new sterile insulin syringes; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document daily dose and site rotation to maintain consistency.
- Safety consideration: Clinical development was discontinued due to safety concerns including reversible kidney toxicity at higher doses. This protocol is for educational purposes only.
Protocol source: PeptideDosages.com
Common questions
Is Adipotide the same as AOD-9604?
No. AOD-9604 is a growth-hormone fragment; Adipotide targets fat-tissue blood vessels.
How does it compare to semaglutide or tirzepatide?
Those are FDA-approved medicines with large human trials. Adipotide has only animal evidence.
Why did the human trial stop?
The registry lists the investigator's request; it does not state a medical reason.
Related in Metabolic Health
Sources and further reading (5)
- Barnhart KF, et al. A peptidomimetic targeting white fat causes weight loss in obese monkeys. Sci Transl Med, 2011.
- ClinicalTrials.gov NCT01262664 (terminated, no results).
- Kolonin MG, et al. Reversal of obesity by targeted ablation of adipose tissue. Nat Med, 2004.
- NIDDK. Prescription medications to treat overweight and obesity.
- Source summary: PeptideDosages.com research overview (rewritten for NVO).